このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Roche Holding マネジメント

マネジメント基準チェック /34

Roche Holding'sの CEO はThomas Schineckerで、 Mar2023年に任命され、の在任期間は 1.25年です。の年間総報酬はCHF 5.34Mで、 23.4%給与と76.6%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0%を直接所有しており、その価値はCHF 701.70K 。経営陣と取締役会の平均在任期間はそれぞれ4.7年と7.3年です。

主要情報

Thomas Schinecker

最高経営責任者

CHF5.3m

報酬総額

CEO給与比率	23.4%
CEO在任期間	1.3yrs
CEOの所有権	0.0003%
経営陣の平均在職期間	4.7yrs
取締役会の平均在任期間	7.3yrs

経営陣の近況

Recent updates

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Apr 17

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Mar 06

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Feb 09

CEO報酬分析

Roche Holding の収益と比較して、Thomas Schinecker の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Dec 31 2023	n/a	n/a	CHF11b
Sep 30 2023	n/a	n/a	CHF11b
Jun 30 2023	n/a	n/a	CHF11b
Mar 31 2023	n/a	n/a	CHF12b
Dec 31 2022	CHF5m	CHF1m	CHF12b
Sep 30 2022	n/a	n/a	CHF14b
Jun 30 2022	n/a	n/a	CHF15b
Mar 31 2022	n/a	n/a	CHF14b
Dec 31 2021	CHF4m	CHF1m	CHF14b
Sep 30 2021	n/a	n/a	CHF14b
Jun 30 2021	n/a	n/a	CHF14b
Mar 31 2021	n/a	n/a	CHF14b
Dec 31 2020	CHF4m	CHF879k	CHF14b
Sep 30 2020	n/a	n/a	CHF14b
Jun 30 2020	n/a	n/a	CHF13b
Mar 31 2020	n/a	n/a	CHF13b
Dec 31 2019	CHF2m	CHF609k	CHF13b

報酬と市場: Thomasの総報酬 ($USD 6.04M ) は、 Swiss市場 ($USD 6.00M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Thomasの報酬は 20% 以上増加しましたが、会社の収益は過去 1 年間で 20% 以上減少しました。

CEO（最高経営責任者

Thomas Schinecker (49 yo)

1.3yrs

在職期間

CHF5,335,592

報酬

Dr. Thomas Schinecker serves as Chairman of the Board at Genentech, Inc. since March 2023. He serves as Chief Executive Officer at Roche Holding AG since March 15, 2023. He has been Chief Executive Officer...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Severin Schwan	Executive Chairman	11.3yrs	CHF11.48m	0.039% CHF 77.4m
Thomas Schinecker	Chief Executive Officer	1.3yrs	CHF5.34m	0.00035% CHF 701.7k
Alan Hippe	Chief Financial & Information Officer	13.2yrs	CHF6.05m	0.0059% CHF 11.9m
Bruno Eschli	Head of Investor Relations	no data	データなし	データなし
Claudia Bockstiegel	General Counsel	4.2yrs	データなし	データなし
Pascale Schmidt	Chief Compliance Officer	4.4yrs	データなし	データなし
Barbara Schadler	Head of Group Communications	4.7yrs	データなし	データなし
Cristina Wilbur	Chief People Officer	8.3yrs	CHF4.25m	0.0018% CHF 3.7m
Nicolas Dunant	Head of Group Media Relations	no data	データなし	データなし
Boris Zaitra	Head of Group Business Development and M&A	no data	データなし	データなし
James H. Sabry	Global Head of Pharma Partnering	5.8yrs	データなし	データなし
Paulo Fontoura	Head of Neuroscience Clinical Development	no data	データなし	データなし

4.7yrs

平均在職期間

57yo

平均年齢

経験豊富な経営陣: ROGの経営陣は経験豊富であると考えられます ( 4.7年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Severin Schwan	Executive Chairman	11.3yrs	CHF11.48m	0.039% CHF 77.4m
Bernard Poussot	Non-Executive Independent Director	9.4yrs	CHF330.00k	0.00013% CHF 260.6k
Ulf Schneider	Director	1.3yrs	データなし	データなし
Andre Hoffmann	Independent Vice Chairman	28.4yrs	CHF402.82k	3.53% CHF 7.1b
Patrick Frost	Independent Non Executive Director	4.3yrs	CHF360.00k	0.00025% CHF 501.2k
Richard Lifton	Non-Executive Independent Director	9.4yrs	CHF346.71k	0% CHF 0
Anita Hauser	Non-Executive Independent Director	7.3yrs	CHF336.16k	0.00040% CHF 801.9k
Jorg Duschmale	Non-Executive Independent Director	4.3yrs	CHF364.59k	データなし
Akiko Iwasaki	Director	1.3yrs	データなし	データなし
Claudia Ricarda Rita Suessmuth Dyckerhoff	Non-Executive Independent Director	8.3yrs	CHF367.02k	0.00034% CHF 681.6k
Jemilah Mahmood	Independent Non-Executive Director	2.3yrs	CHF272.50k	データなし

7.3yrs

平均在職期間

57yo

平均年齢

経験豊富なボード: ROGの取締役会は経験豊富であると考えられます ( 7.3年の平均在任期間)。

Roche Holding マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Roche Announces Management and Board Committee Changes

Roche Holding AG, Annual General Meeting, Mar 12, 2024

Recent updates

Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

Roche Holding AG Announces U.S. Food and Drug Administration Accepted the New Drug Application and Granted Priority Review to Inavolisib, an Investigational, Oral Therapy, in Combination with Palbociclib (Ibrance®) and Fulvestrant

Roche Announces Management and Board Committee Changes

Roche Receives FDA Device Designation for Blood Test Measuring Lp(a)

Roche Reports Positive Phase I Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People with Obesity

Roche Announces FDA Approval of One of the First HPV Self- Collection Solutions in the U.S., Expanding Access and Screening Options to Help Eliminate Cervical Cancer

Roche Holding AG Provides Earnings Guidance for the Year 2024

FDA Approves Roche’s Alecensa as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer

Roche Holding AG Announces Data from the Phase III OCARINA II Study (S31.006) of OCREVUS®? (ocrelizumab)

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Roche Receives FDA Breakthrough Device Designation for Blood Test to Support Early Alzheimer's Disease Diagnosis

Roche Receives FDA Approval for the First Molecular Test to Screen for Malaria in Blood Donors

Roche Holding AG, Annual General Meeting, Mar 12, 2024

Upcoming dividend of CHF9.60 per share

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Roche and Alnylam Report Positive Topline Results from the Phase II KARDIA-2 Study in People with Hypertension

Roche Announces FDA Approves Xolair as First and Only Medicine for Children and Adults with One or More Food Allergies

Roche Launches Three New Factor Xa Inhibitor Coagulation Tests to Meet Growing Patient Need

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Roche Holding's (VTX:ROG) Soft Earnings Are Actually Better Than They Appear

Full year 2023 earnings: EPS and revenues miss analyst expectations

Dividend increased to CHF9.60

Roche Announces New 72-Week Data from Two Global Phase III Studies, BALATON and COMINO, Evaluating Vabysmo® (Faricimab) in Macular Edema Due to Branch and Central Retinal Vein Occlusion (BRVO and CRVO)

Roche Holding AG Proposes Dividend

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

European Commission Approves Roche's Tecentriq SC, the EU's First PD-(L)1 Cancer Immunotherapy Subcutaneous Injection for Multiple Cancer Types

Market Cool On Roche Holding AG's (VTX:ROG) Earnings

Roche Holding AG to Report Fiscal Year 2023 Results on Feb 01, 2024

Roche Announces New Data from Its CD20xCD3 T-Cell Engaging Bispecific Antibody Programme Were Presented At the 65Th American Society of Hematology Annual Meeting & Exposition

Roche Announces New Data Reinforce the Benefit of Early Preventative Treatment with Hemlibra for Babies with Severe Haemophilia A

Roche Presents Positive Results from the Phase III INAVO120 Study Evaluating Inavolisib in Combination with Palbociclib and Fulvestrant as a First-Line Treatment for People with PIK3CA-Mutation

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Roche Holding AG (SWX:ROG) entered into a definitive merger agreement to acquire Carmot Therapeutics Inc. from a group of shareholders for approximately $2.7 billion.

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Launches Automated Serology Hepatitis E Virus Tests, Including A Test to Detect Acute Hev Infections, Recommended in the New Who 2023 Essential Diagnostics List

Roche's Subcutaneous Injection of Tecentriq Recommends by the EU's CHMP for Multiple Cancer Types

Roche Announces its Elecsys NfL Test Receives FDA Breakthrough Device Designation from the U.S. Food and Drug Administration

Roche Announces EMBARK Trial in Duchenne Muscular Dystrophy

United States Food and Drug Administration Approves Roche's Vabysmo for the Treatment of Retinal Veinocclusion (RVO)

Roche Holding AG Confirms Outlook for 2023

Roche Announces Roche IL-6 Is the First Immunoassay Approved to Aid Sepsis Diagnosis in Newborns

Roche Announces New Clinical and Real-World Data for Orevus (Ocrelizumab)

Roche Holding AG Announces Late-Breaking Data from the Phase III Ocarina III Study as an Investigational Twice-Yearly, 10-Minute Subcutaneous Injection on Pharmacokinetic, Biomarker, and Mri Measures in Patients with Relapsing or Primary Progressive Multiple Sclerosis

Roche Presents Positive Results from the Primary Analysis of the Ongoing Rainbowfish Study Assessing the Efficacy and Safety of Evrysdi

Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran

Roche’S Alecensa Delivers Unprecedented Phase III Results for People with ALK-positive early-stage lung cancer

Roche Holding AG Tecentriq Becomes the First Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy Available to Patients in Great Britain, Reducing Treatment Time to Just Minutes

Is Roche Holding (VTX:ROG) A Risky Investment?

Roche Provides Update on Phase III Skyscraper-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer

New minor risk - Earnings quality

Roche Holding AG Confirms Earnings Guidance for the Year 2023

Roche Announces New Clinical and Real-World Data for Vabysmo at ASRS Reveal Improved Outcomes for People with Two Leading Causes of Vision Loss

Roivant Sciences Reportedly Near Deal to Sell Stomach Drug to Roche for over $7 Billion

Roche Announces Positive Phase III Results for Roche’s OCREVUS (ocrelizumab) Twice a Year, 10-minute Subcutaneous Injection in Patients with Multiple Sclerosis

European Commission Approves Roche Holding AG's Fixed-Term Columvi (Glofitamab) for People with Relapsed or Refractory Diffuse Large B-Cell L-Cell Lymphoma

Roche Receives FDA Clearance for Additional Alzheimer's Disease Cerebrospinal Fluid Assays, Supporting Timely Diagnosis and Treatment Decision-Making

Roche Looking to Sell or Shut Down Vacaville, California Plant

Does Roche Holding (VTX:ROG) Have A Healthy Balance Sheet?

Roche Announces U.S. Food and Drug Administration Accepted Supplemental Biologics License Application for Vabysmo

Upcoming dividend of CHF9.50 per share at 3.6% yield

Roche Announces Positive New Data from Two Global phase III studies, BALATON and COMINO

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34